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Human pluripotent stem cells are the foundations of regenerative medicine. However, the worst possible
complication of using pluripotent stem cells in therapy could be iatrogenic cancerogenesis. Nevertheless, despite
the rapid progress in the development of new techniques for induction of pluripotency and for directed
differentiation, risks of cancerogenic transformation of therapeutically implanted pluripotent stem cells still persist.
'Above all, do no harm', as quoted from the Hippocratic Oath, is our ultimate creed. Therefore, the primary goal in
designing any therapeutic regimes involving stem cells should be the elimination of any possibilities of their
neoplasmic transformation. I review here the basic strategies that have been designed to attain this goal: sorting
out undifferentiated, pluripotent stem cells with antibodies targeting surface-displayed biomarkers; sorting in
differentiating cells, which express recombinant proteins as reporters; killing undifferentiated stem cells with toxic
antibodies or antibody-guided toxins; eliminating undifferentiated stem cells with cytotoxic drugs; making
potentially tumorigenic stem cells sensitive to pro-drugs by transformation with suicide-inducing genes; eradication
of differentiation-refractive stem cells by self-triggered transgenic expression of human recombinant DNases. Every
pluripotent undifferentiated stem cell poses a risk of neoplasmic transformation. Therefore, the aforementioned or
other novel strategies that would safeguard against iatrogenic transformation of these stem cells should be
considered for incorporation into every stem cell therapy trial.Introduction
Healthy cells of an embryo developing in utero are pluri-
potent. From a single cell zygote, they proliferate into the
trillions of cells in an adult human. They also differentiate,
through the three main germ layers, into the adult cells
of tissues and organs. Most of the mature cells do not pro-
liferate, but fulfill complex physiological processes, for
example, neurons or cardiomyocytes. Some of the cells
keep proliferating and differentiating as part of their regu-
lar modus operandi (for example, bone marrow or skin
epithelium). During development, these two processes are
accompanied by a third, apoptosis - selective cell death of
non gratae cells in maturing organs. This balance isCorrespondence: mm@pbmef.org
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2014destroyed in various processes of pathology, of which at
least two are worth discussing here.
First, in cancer, cells acquire the ability to proliferate
in an uncontrolled manner. In embryonal carcinomas,
the cells have many features identical to the cells of de-
veloping embryos. In anaplastic cancers, the cells dedif-
ferentiate and lose the features of the tissues from which
they originated, so that the lineage of their origin is
nearly impossible to determine. In teratomas, the cells
proliferate and differentiate, but not in synchrony with
the entire body and its established architecture. Apop-
totic and repair mechanisms should ensure that cancer
cells are eliminated and tissues reconstructed, but
instead these mechanisms are either mutated, disabled,
or cannot discriminate cancer cells from healthy cells.
Thus, discovering the mechanisms of proliferation, dif-
ferentiation, immune response, and death may lead not
only to cures for cancers, but also therapies that guide
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Table 1 Strategies safeguarding pluripotent stem cell therapy against iatrogenic cancerogenesis
Authors Stem cells Key reagent Procedure Mechanism
Fong et al. [28] Human embryonic Mouse monoclonal antibodies
anti-SSEA-4, anti-TRA-1-60
FACS, MACS Depletion of SSEA-4+,
TRA-1-60 + hESCs
Tang et al. [30] Human embryonic Mouse monoclonal antibodies
anti-SSEA-5, CD9, CD90 or
anti-SSEA-5, CD50, CD200





Human embryonic Mouse monoclonal antibody
anti-claudin-6
FACS Depletion of claudin-6+
hESCs
Killing by toxins linked to
antibodies
Human induced pluripotent




FACS Separation of fate-specific
subpopulations of GFP +
hESCs




MACS, FACS Depletion of SSEA-4+,
TRA-1-60+ non-
differentiating hiPSCs




Monitoring and selection of
differentiating cells















van Laake et al.
[34]
Murine induced pluripotent Fusion protein expressed from
NKX2-5-EGFP
FACS Selection of differentiating
cells
Chung S et al.
[35]
Murine embryonic Fusion protein expressed from
SOX1-GFP
FACS Selection of differentiating
cells
Malecki et al. [10] Human autologous induced
pluripotent
Fusion fluorescent proteins
expressed under promoters for




Monitoring and selecting of
differentiating cells










cells + killing with toxic
antibody









Human induced pluripotent PluriSIn#1 Reagent dissolved in media Inhibition of SCD1 leading
to UPR, ER stress, and
apoptosis
Conesa et al. [40] Murine embryonic Benzethonium chloride,
methylbenzethonium chloride
Reagent dissolved in media Mitochondrial membrane
permeability, apoptosis
Human induced pluripotent
Lee et al. [41] Human embryonic Human
induced pluripotent









S18 (N-oleoyl serinol) Reagent dissolved in media Apoptosis
Schuldiner et al.
[44]
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Table 1 Strategies safeguarding pluripotent stem cell therapy against iatrogenic cancerogenesis (Continued)











Chen et al. [48] Murine undifferentiated
pluripotent stem
Recombinant cytosine deaminase





Malecki et al. [50] Human autologous induced
pluripotent
Human recombinant DNASE1,





EB, embryoid body; EGFP, enhanced green fluorescent protein; ER, endoplasmic reticulum; FACS, fluorescence activated cell sorting; FGFR, fibroblast growth factor
receptor; GCV, ganciclovir; GFP, green fluorescent protein; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; HSV, herpes simplex
virus; MACS, magnetic activated cell sorting; SCD1, stearoyl-CoA desaturase 1; SSEA, stage specific embryonic antigen; TK, thymidine kinase; TRA, tumor related
antigen; UPR, unfolded protein response.
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cue and regeneration responses. Adult cells gain the
ability to replace damaged cells and to heal the injured
tissue completely and with fully restored functions, but
without triggering tumor formation (for example, epithe-
lium in skin injuries). Unfortunately, in some cases the
natural responses are not sufficient (for example, cardiac
stem cells in myocardial infarctions). The means to con-
trol these responses and to enhance them using pharma-
cotherapeutics or transgenes are not yet within our
clinical management repertoire. Administration of pluri-
potent cells is aimed at supporting the regeneration pro-
cesses of injured tissues, but without inflicting iatrogenic
harm.
Stem cells form the therapeutic basis for regeneration
of organs injured by disease, for reconstruction of tissues
damaged by iatrogenic effects of therapies, for rejuven-
ation of systems affected by aging, for correction of con-
genital defects caused by genetic mutations, and even
for delivery of therapeutic transgenes [1-5]. This wide
spectrum of potential applications is based upon the
unique capabilities of pluripotent stem cells not only to
self-renew into the same kind of undifferentiated cells,
but also to differentiate into a variety of specialized tis-
sues. Biomarkers displayed on the surfaces of undifferen-
tiated cells, and that change upon differentiation of
these cells, are the same for human embryonal carcin-
omas of ovaries and testes, human embryonic stem cells
(hESCs), and human induced pluripotent stem cells
(hiPSCs). Importantly, induced pluripotent stem cells
(iPSCs) do not present ethical concerns associated with
destroying human embryos needed for gaining embry-
onic stem cells [6,7]. Moreover, autologous human in-
duced pluripotent stem cells (ahiPSCs) reduce the risks
of rejection of implanted cells by the immune system of
recipients [8]. The essential problem for successful re-
generative therapy, recruitment and retention of pluripo-
tent stem cells to the sites of therapeutic intervention,has recently been addressed by introduction of genetic-
ally engineered, heterospecific, polyvalent antibodies
[9-11]. However, all engineered pluripotent stem cells
carry a risk of neoplastic transformation, which has
prompted work on measures to safeguard against this
[12-19]. In fact, the first reported induced stem cells
were generated by transfection with sets of genes for
transcription factors known as strong oncogenes (MYC
and KLF4). Furthermore, they were cloned into integrat-
ing, and thus potentially cancerogenic, retroviral vectors.
Accordingly, one of the tests for pluripotency of these
cells is their ability to form teratomas in nude mice.
Current research is moving towards using non-
integrating viral vectors, changing the number and com-
position of transcription factors, enhancing and simplify-
ing induction of pluripotency by small molecules, the
use of systems that ensure differentiation of progenitors
into the desired lineage, as well as towards bypassing in-
duction of pluripotency altogether by directed trans-
differentiation [20-27].
Nevertheless, despite rapid progress in the develop-
ment of new methods for inducing pluripotency and for
directed differentiation, completely erasing genomic
memory may require solid reversal of differentiation,
and differentiation refractive cells may contaminate
batches of therapeutic cells planned for therapeutic im-
plantation. Indeed, several cases of neoplasms grown
from implanted iPSCs have been reported. Therefore,
the serious risk of neoplasmic transformation of induced
pluripotent stem cells persists.
Review of safeguarding strategies
'Above all, do no harm', as quoted from the Hippocratic
Oath, is our ultimate creed. Therefore, the primary goal
in designing any therapeutic regime involving stem cells
should be the elimination of any possibilities for their
neoplastic transformation. I review here the basic strat-
egies that have been designed to attain this goal: sorting
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bodies targeting surface-displayed biomarkers; sorting in
differentiating cells, which express recombinant proteins
as reporters; killing undifferentiated stem cells with toxic
antibodies or antibody-guided toxins; eliminating undif-
ferentiated stem cells with cytotoxic drugs; making po-
tentially tumorigenic stem cells sensitive to pro-drugs by
transformation with suicide-inducing genes; and eradica-
tion of differentiation-refractive stem cells by self-
triggered transgenic expression of human recombinant
DNases.
Sorting out undifferentiated, pluripotent stem cells
Undifferentiated, pluripotent stem cells display unique
surface biomarkers. Stage specific embryonal antigen
SSEA-3 and SSEA4 are the most established biomarkers
of pluripotent stem cells displayed on embryonic stem
cells (ESCs), iPSCs, and cells of embryonal carcinomas
of the testes and ovaries. Display of these biomarkers is
quickly downregulated upon differentiation of the stem
cells. However, stem cells refractive to differentiation re-
tain their surface display profiles. Monoclonal antibodies
raised in mice or nano-antibodies and aptamers synthe-
sized chemically target these stem cells’ biomarkers.
Each of them, after being modified with fluorochromes
or superparamagnetic chelates, may facilitate fluores-
cence activated cell sorting (FACS) or magnetic activated
cell sorting of the undifferentiated, pluripotent stem
cells.
Antibodies against SSEA-3 and SSEA-4 and tumor re-
lated antigen 1–60 and 1–81 (TRA-1-60 and TRA-1-81)
were first developed and used for not only monitoring,
but also selection of undifferentiated ESCs and iPSCs. For
example, after directing differentiation of ahiPSCs towards
the endothelial or myocardial lineages, the undifferenti-
ated cells were sorted out by superparamagnetic or
fluorescent antibodies [9-11,28,29]. This procedure elimi-
nated potentially tumorigenic stem cells.
SSEA-5 was identified on human pluripotent stem
cells. Monoclonal antibody raised against SSEA-5 facili-
tated separation of SSEA-5+ and SSEA-5- cell popula-
tions [30]. After implanting an under the kidney capsule
in immunodeficient mice, all SSEA5+ cells grew into tu-
mors (7 out of 7 tested), while SSEA-5- cells reduced the
number of tumors (3 out of 11 tested). As such, the anti-
bodies to SSEA-5 were insufficient alone to separate all re-
sidual tumorigenic cells. Therefore, further reduction of
sizes and numbers of forming tumors was accomplished
by combining antibodies against SSEA-5 with two other
antibodies, resulting in two combinations: SSEA-5, CD9,
and CD90; or SSEA-5, CD50, and CD200 [30].
Claudin-6 is a member of the claudin family, which
contributes to formation of tight junctions. It is dis-
played on hESCs and hiPSCs but is dispensable for theirsurvival and renewal [31]. This molecule is also expressed
on cancer cells, influencing their anchorage properties. It
is retained during pluripotency. Fluorescently modified
monoclonal anti-claudin-6 antibodies facilitated separ-
ation by FACS of cells displaying claudin 6 from those not
displaying it. After injection of these two populations
into immunodeficient mice, tumors grew from only the
claudin-6-positive cells, but not from the claudin-6-
negative cells. This strategy was further enhanced by link-
ing the anti-claudin-6 antibody with toxins (see below).
Mouse monoclonal antibodies anti-SSEA-4, anti-TRA-
1-60, anti-fibroblast growth factor receptor 1, anti-
CD133, and anti-CD135 were used to separate subpopu-
lations of stem cells from green fluorescent protein
(GFP) + hESCs. GFP+/CD133+ cells differentiated to-
ward ectoderm as determined by gene expression for
nestin, which was not the case with GFP+/CD133- cells.
CD135+/GFP + and CD135- hESCs gave rise to tissues
representing all three embryonic germ layers. These
studies suggest lineage preferences within hESCs rather
than uniform pluripotency. In such cases, these subpop-
ulations may differ in their response to differentiating
factors, as well as in their tumorigenicity [29].
Sorting in differentiating cells expressing green
fluorescent protein as reporters
Inducing and maintaining pluripotency involves expres-
sion of specific genes encoding the appropriate pluripo-
tency transcription factors. The most critical are
NANOG, OCT4, and SOX2. Directed differentiation of
iPSCs involves monitoring the expression of differenti-
ation lineage-specific genes. For example, expression of
MEF and GATA is the earliest sign of myocardial differ-
entiation. Transgenic expression of OCLN5 (endothelial
occludin), CLDN5 (endothelial claudin), PECAM1 (plate-
let/endothelial cell adhesion molecule 1), CDH5 (cad-
herin), TJP1 (zona occludens), and CTNNB (catenin) is
the earliest sign of vasculogenesis [10]. Genes for GFPs
and their mutants, under control of promoters or fused
with coding sequences for the proteins, which are
uniquely specific for undifferentiated or differentiated
cells, serve well as reporters of these phenomena. If un-
differentiated pluripotent stem cells are transformed to
express GFPs as reporters, then as long as they remain
undifferentiated, they emit fluorescence upon illumin-
ation with specific wavelengths. This facilitates their
sorting out with FACS or eradication through laser abla-
tion. If differentiating cells in cultures or embryoid bod-
ies are expressers, then only differentiating cells can be
selected and non-fluorescent cells can be abandoned.
Both approaches have been applied to monitor fates of
ESCs and iPSCs.
The hESCs were transfected with constructs for
EGFP (enhanced GFP) driven by the OCT4 promoter
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embryoid body formation and in vitro differentiation,
their expression was validated as representing endogen-
ous expression of OCT4 in undifferentiated hESCs.
OCT4 small interfering RNA downregulated this expres-
sion, resulting in reduced differentiation [32]. Similar
studies were conducted by expressing EGFP under
the Rex1 (REX-EGFP) murine promoter [33]. In both
cases, fluorescent reporters facilitated identification and
separation.
hiPSCs were transfected with GFP constructs under
the NANOG promoter. This resulted in expression of
the fluorescent transcription factor (NANOG-GFP) in
undifferentiated cells. Upon formation of embryoid bod-
ies, expression of GFP indicated the presence of undif-
ferentiated cells. GFP-positive and -negative embryoid
bodies were injected into nude mice; the first developed
tumors, while the latter did not. This approach guided
selection of non-tumorigenic cells within embryoid
bodies.
An alternative strategy was developed by genetic en-
gineering constructs coding for fluorescent proteins
under control of genes expressed in differentiating cells
or as fusions with those genes’ products. Expression of
fluorescent reporters served as a guide for selection of
progenitors for further differentiation. Mouse iPSCs
were transfected with the transgene for a fusion protein
of the early cardiac transcription factor NKX2-5 and a
GFP reporter (NKX2-5-GFP) and then directed to differ-
entiate [34]. Fluorescent transgene expression products
facilitated selection of NKX2-5/GFP + cardiac progeni-
tors, while undifferentiated cells were discarded. Simi-
larly, mouse ESCs were transfected to express GFP
under the SOX1 promoter (SOX1-GFP) [35]. This pro-
vided an opportunity for positive selection of fluorescing
cells.
ahiPSCs were directed to differentiate into endothelial
cells as a means to regenerate infarcted myocardium by
revascularization. The processes of differentiation were
monitored by combinations of transduction with vectors
carrying genetically engineered constructs for GFP and
its mutants as fusions with OCLN5 (endothelial occlu-
din), CLDN5 (endothelial claudin), PECAM1 (platelet/
endothelial cell adhesion molecule 1), CDH5 (cadherin),
TJP1 (zona occludens), and CTNNB (catenin) and label-
ing with superparamagnetic and fluorescent synthetic
antibodies against those proteins [10].
Killing pluripotent stem cells with cytotoxic antibodies or
antibody-guided toxins
Immunotherapy for cancer relies upon direct cytotox-
icity or the ability to elicit immune cytotoxic responses
by selected clones of antibodies towards cancer cells
with surface-displayed mutated and/or upregulated geneexpression products - cell surface displayed cancer bio-
markers [31]. Alternatively, the antibodies can be linked
to toxins, chemotherapeutics, cancer cell suicide-
inducing genes, or radionuclides, which then serve as
carriers delivering deadly cargo to the targeted cancer
cells. Ideal examples of such strategies are provided by
therapies built around EGFRvIII, which encodes a mutant
epidermal growth factor receptor missing a large portion
of its extracellular domain. As a result, a portion of this
extracellular domain has a different molecular structure to
the corresponding portion in the wild-type receptor and is
thus a different immunogen. This creates the difference in
immunogenic specificity and absence of cross-reactivity
between the antibodies against those receptors. Therefore,
EGFRvIII is a unique target for developing targeted ther-
apies, vaccines, and immunotherapeutics. The same prin-
ciples are applied to developing strategies that utilize
antibodies to destroy undifferentiated stem cells. First and
foremost, however, these strategies rely upon identification
of specific biomarkers - molecules displayed exclusively
on surfaces of undifferentiated, pluripotent stem cells.
Podocalyxin like protein 1 has been identified on the
surfaces of stem cells in hESC lines (HES-2, HES-3,
HES-4) and in a pluripotent cell line (NCCIT) derived
from non-seminomatous germ cell tumors. A monoclo-
nal antibody against this protein demonstrated cytoxicity
against undifferentiated cells, but did not interfere with
the progress of differentiating cells [36-38]. Moreover,
since natural antibodies with their high molecular
weights (IgG, 150 kDa; IgM, 750 kDa) do not penetrate
well into embryoid bodies and tissues, single chain vari-
able fragments were engineered with a much smaller
molecular weight (20 kDa) and a thus much smaller
hydrodynamic cross-section. This resulted in much bet-
ter penetration and much higher efficacy in elimination
of potentially tumorigenic stem cells [38].
Claudin-6 is one of the biomarkers of undifferentiated
pluripotent hESCs and hiPSCs. Monoclonal antibodies
against claudin-6 have been modified with fluorochromes
and used for sorting out these cells by FACS in order to re-
duce the risk of tumor growth. As an alternative strategy,
this antibody was used to guide toxins to the marked stem
cells. After attaching to the stem cells, this mouse mono-
clonal antibody was a target for an anti-mouse monoclonal
antibody delivering a saporin toxin [31]. Upon this targeted
delivery, the toxin had a selective, devastating effect on the
claudin-6-expressing stem cells.
Treatment with cytotoxic molecules
Progression of cancer is driven by uncontrolled prolifera-
tion of cancer cells. Chemotherapies exert cytostatic and/
or cytotoxic effects on these proliferating cancer cells. The
clinical efficacy of chemotherapies is contingent upon
their selective discrimination, in intake and efficacy,
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by cancer cells and/or the greater the sensitivity of cancer
cells to a drug relative to healthy cells, then the better the
therapeutic efficacy and the lower the amount of side ef-
fects. Therefore, therapeutic doses in clinical oncology are
at levels that maximize killing of cancer cells (effective
doses) while minimizing harm to healthy cells (side
effects). The same principle is proposed when using drugs
for killing pluripotent stem cells threatening to develop
into neoplasms.
PluriSIn#1 demonstrated selective efficacy in elimination
of undifferentiated iPSCs and ESCs [39]. To identify this
drug, human pluripotent stem cells in matrigel were ex-
posed for 12 hours to various compounds from a high-
throughput screen of 52,448 small molecules - a subset of
the Hoffmann-La Roche diverse chemical entities com-
pound library. PluriSIn#1 inhibits stearoyl-CoA desaturase-
1, an enzyme involved in metabolism of monounsaturated
fatty acid. This leads to apoptosis of the treated cells [38].
Benzethonium chloride and methylbenzethonium chlor-
ide are quaternary ammonium salts. They are better
known as effective antimicrobial agents, including for
treatment of the 'superbug' methicillin-resistant Staphylo-
coccus aureus, which killed more people than AIDS in
2005. They have also been used as anticancer agents. They
were selected after screening a library of 1,120 chemicals
to identify those that induce death of undifferentiated
ESCs [40]. Their pharmacological mechanism of action in-
volves loss of mitochondrial membrane potentials and
activation of caspases. This leads to triggering of the apop-
totic signaling pathways and activation of the DNases.
They were effective in killing murine ESCs, while having
no effect on murine adult fibroblasts. Similarly, human
fibroblast-derived induced stem cells were sensitive to
these salts, but sourced fibroblasts were not.
Quercetin and YM155 were used to treat undifferenti-
ated hESCs, iPSCs, and spontaneously differentiated
cells from embryoid bodies [41]. Both reagents did not
affect processes of differentiation, which were tested by
relative expression levels of lineage-specific differenti-
ation marker genes (AFP, FOXA2, GATA6 for endoderm;
Brachyury T, TnTc, IGF2 for mesoderm; and PAX6,
NCAM for ectoderm). These molecules inhibited forma-
tion of tumors in nude mice after xenografting [40].
Metformin suppressed Oct4 in stem cells without
interfering with the Oct4-independent abilities of these
cells to differentiate into tissues [41]. This is an add-
itional application of a drug regularly used for treatment
of diabetes. As the outcome, it prevented occurrence or
caused reduction in the size and weight of teratoma-like
masses after transplantation of the murine iPSCs into
immunodeficient mice [42].
In tumors formed after engraftment of embryoid body
cells into mouse brains, Oct4 colocalized with prostateapoptosis response-4 (PAR-4), a protein mediating
ceramide-induced apoptosis during neural differentiation
of hESCs. Treatment of undifferentiated stem cells with
the ceramide analogue N-oleoyl serinol (S18) induced
formation of a complex between PAR-4 and protein
kinase C zeta, which resulted in inhibition of PAR-4 and
apoptosis of the treated cells. Untreated cells formed nu-
merous tumors [43].
Clostridium perfringens enterotoxin binds specifically
to members of the claudin protein family. Upon binding
of this toxin by a cell, the cell's membrane permeability
rapidly changes, resulting in the cell's death. Since pluri-
potent, undifferentiated stem cells display claudin-6 they
are a target for this toxin. Indeed, 1 hour in vitro treat-
ment of undifferentiated stem cells in culture was suffi-
cient to kill all of them [31]. In vivo, no tumors were
detected in mice treated with Clostridium perfringens
enterotoxin (none out of four), while all the untreated,
xenografted mice developed tumors (four out of four)
[31].
Killing pluripotent stem cells by transfection with genes
inducing cell suicide upon exposure to pro-drugs
Herpes simplex virus (HSV)-thymidine kinase (TK) in
combination with ganciclovir (GCV) is the most widely
used strategy for suicide gene therapy of cancer
[4,44-48]. Unlike cellular TK, HSV-TK has a range of
specificities, including pyrimidine, the pyrimidine analog
deoxycytidine, guanosine, and the acyclic guanosine nu-
cleoside analogue GCV. Although GCV is the pro-drug
of choice, its application is limited due to high toxicity.
In non-transfected cells, cellular TK catalyzes the trans-
fer of phosphate from ATP to thymidine to produce
dMTP. In transfected cells, HSV-TK catalyzes this reac-
tion also for the mentioned analogs. These nucleoside
analogs, once phosphorylated, are further phosphory-
lated by cancer cell kinases to triphosphates. Some of
these analogs, including GCV, are capable of inhibiting
DNA synthesis through arrest at the G2/M check point,
which triggers apoptosis. Transportation of the phos-
phorylated analogs through the gap junction or via
apoptotic vesicles to the neighboring cells leads to their
apoptosis. This is known as a bystander effect. This
strategy has been successfully adapted to kill undifferen-
tiated stem cells.
The plasmid construct was engineered to contain the
gene for HSV-TK under the PGK promoter (PGK-HSV-
TK) [44]. It was transfected using ExGen500 into hESCs.
Upon exposure to varying concentrations of GCV (2 ×
10−8 M to 2 × 10−5 M) in vitro, the transfected hESCs
died, while the non-transfected hESCs were unaffected.
The efficacy was quantified based upon flow cytometry
of hESCs stably transformed with GFP. Some of the
transfected cells reversed (1 × 10−6 to 1 × 10−7). The
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mice. Tumor growth was inhibited after treatment with
GCV, but progressed in the absence of such treatment
in control mice.
PGK-HSV-TK presented a risk of affecting all prolifer-
ating cells. To reduce that risk, a viral vector was engi-
neered in which HSV-TK was set under the control of
the OCT4 promoter [45]. After transforming hESCs, this
strategy limited the effects of GCV treatment to undif-
ferentiated cells only with active transcription factors
unique to the pluripotent stem cells [45].
The viral vector may promote cancerogenesis through
random incorporation that disrupts cancer suppressing
or repairing genes. To address this problem, the bacter-
ial artificial chromosome vector carrying NANOG was
re-engineered by inserting an IRES-TKSR39-IRES-Puro-
IRES-EGFP expression cassette flanked by two LoxP
sites. This HSVTK construct was inserted into the
NANOG locus by homologous recombination [46]. After
xenografting into nude mice, tumor formation was elim-
inated in mice treated with GCV (0/10), compared with
high tumorigenicity in non-treated mice (4/4). Further-
more, the HSV-TK transduced cells were effectively di-
rected to differentiate with retinoic acid, while tested for
PAX6 (ectoderm), PECAM (mesoderm), 3SCL, and AFP
(endoderm) gene expression. Therefore, the construct did
not interfere with these cells' capability to differentiate.
Suicide gene transfection was also applied to reduce
the risk of iatrogenic cancerogenesis in hiPSCs. The
hESCs and hiPSCs were infected with lentivirus engi-
neered to deliver HSV-δTK under control of the
NANOG or EF1 promoters [47]. The genetically modi-
fied cells retained their ability to self-renew and differen-
tiate. In vitro, almost no HSV-δTK modified cells were
still viable in the group treated with 5 μg/ml for 5 days,
while there were no toxic effects on the non-modified
cells. The rate of apoptosis increased to 90% on the fifth
day of treatment. In vivo, the most significant result of
the study was selective ablation of undifferentiated pluri-
potent stem cells and progression of differentiating cells
towards the three germ layers.
Cytosine deaminase catalyzes hydrolysis of cytosine to
uracil with release of ammonia. If endonucleases
recognize modified sites, then the phosphodiester bonds
are broken, while initiating repair by incorporation of
new cytosines. This pharmacological mechanism is uti-
lized for cancer suicide gene therapy - that is, if the non-
toxic pro-drug 5-fluorocytosine is provided, then cytosine
deaminase converts it into 5-fluorouracil, which inhibits
cancer cell growth. This strategy has been successfully ap-
plied in selective killing of tumor-initiating murine pluri-
potent stem cells by expressing recombinant cytosine
deaminase or δTK under control of the EF1α or NANOG
promoters [48].Eradication of human induced pluripotent stem cells by
proliferation-triggered transgenic expression of recom-
binant DNases
Despite great advances towards development of reliable
strategies for eliminating potentially tumorigenic cells
from batches planned for therapeutic implantation, a
couple of issues are worth improving before translating
these strategies into clinics. First, the discussed strategies
do not have a self-triggered safeguarding mechanism,
but instead require constant monitoring, which is not
easy in patients. Second, they require preventive applica-
tion of pro-drugs, but we know from oncology clinics
that all the pro-drugs have serious side effects, in par-
ticular GCV. Third, pro-drugs may cause mutations in
genomic DNA in the germ cells, introducing the risk of
genetic disorders in offspring. These reasons have
prompted work on developing a strategy that would in-
corporate a self-triggered feed-back loop while not rely-
ing upon provision of toxic reagents. Protecting the
fertility of patients suffering from cancers and eliminat-
ing the risk of genetic disorders in their offspring
present identical problems, and attained solutions are
considered here.
Cancer development is driven by uncontrolled prolif-
eration of cancer cells. The key element of their prolifer-
ation involves passing the G1 > S check-point, which
initiates replication of genomic DNA. In various cancers,
elements of this transition are strongly stimulated by
complex and multiple signaling pathways. For example,
in brain, lung, testicular, or ovarian cancers, expression
of the EGFR gene, which encodes the epidermal growth
factor receptor (EGFR), is greatly upregulated. Targeted
therapies aim to interrupt these pathways, but cancer
cells have the ability to develop alternative pathways, to
repair damaged DNA, to expel therapeutics, and to re-
verse apoptotic processes, as long as they retain intact
genomic DNA. Considering the aforementioned data, an
entirely different strategy has been developed, consisting
of genetically engineered DNA constructs for the recom-
binant DNases controlled by the EGFR promoter, syn-
thetic antibody-guided biotag-targeted delivery of these
constructs only into cancer cells expressing mutated
EGFRs or over-expressing them, expression only in can-
cer cells, and intranuclear trafficking of the transgeni-
cally expressed DNases [49].
The same principles guided development of the strat-
egy aimed at eradication of all undifferentiated pluripo-
tent stem cells [50]. The ahiPSCs were directed to
differentiate into endothelial or myocardial lineages.
Thereafter, these cells were transfected with vectors car-
rying the transgenes for human recombinant DNASE1,
DNASE1L3, DNASE2, and DFFB, while guided by anti-
SSEA-4 and anti-TRA-1-60 synthetic antibodies. There-
fore, the vectors delivered the transgenes to pluripotent,
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tiation was monitored by expression of GFP and its mu-
tants controlled by MEF and GATA promoters. Early
endothelial differentiation was monitored by expression
of GFP controlled by OCLN5, CLDN5, PECAM1,
CTNNB, or CDH5 promoters. Proliferation was moni-
tored by expression of GFP mutants controlled by the
POLA1 promoter. If the hiPSCs did not differentiate but
retained their pluripotency and specific cell surface dis-
play profiles and kept proliferating, then they expressed
the human recombinant DNases, which were completely
effective in degrading genomic DNA, thus causing the
death of these potentially tumorigenic stem cells.
Future directions
The first sets of transcription factors used to reprogram
adult cells into iPSCs relied on provision of potent onco-
genes (MYC and KLF) and transcription factors known
to be overexpressed in undifferentiated stem cells. Since
then, several other combinations of factors inducing
pluripotency have been designed and tested, but a lot
of work remains to be done [17-20]. The immediate
studies will define the complete spectra of pluripotency-
inducing transcription factors and the multiple path-
ways/mechanisms controlling them, so that full pluripo-
tency can be attained and controlled differentiation can
be pursued without a risk of tumorigenesis in vivo. The
results of these studies will affect two strategies of clin-
ical practice. First, autologous pluripotent stem cells will
be generated by dedifferentiation of donors’ adult cells,
expanded and induced to differentiate into therapeutic-
ally desired lineages. After identification of the exact pat-
terns of gene expression during development, it may not
be necessary to fully erase the epigenetic memory of
adult cells, but only to the stage sufficient for the lineage
switch. Moreover, it may become possible to alter their
immunological profiles, so that they will not trigger re-
jection if used as heterologous transplants. Second, iden-
tification of these genes’ expression patterns will open
opportunities for direct lineage reprogramming without
dedifferentiation to the pluripotency stage at all [10,21].
Seamless, functional integration with the host’s healthy
tissue will be the ultimate test of whether any new ap-
proaches are successful.
Not only function, but also integration of regenerating
cells into the architecture and the correct location in the
host’s organs is essential. Recruitment and retention of
the iPSCs in sites of therapeutic intervention have been
significantly enhanced by anchoring them with the het-
erospecific polyvalent antibodies. Aforementioned ad-
vances in controlling the processes of differentiation will
direct further pursuits of that strategy in clinical trials.
First, hiPSCs will be anchored through the displayed re-
ceptors [9-11]. This approach will require application ofall of the safeguards against tumorigenesis reviewed
above. Second, as an alternative, the progenitors gener-
ated through in vitro-induced differentiation or through
directed trans-differentiation will display lineage-specific
biomarkers that will serve as tagging points for anchor-
ing them with heterospecific antibodies. Thorough sort-
ing in of progenitors and sorting out of undifferentiated
cells will eliminate the risk of tumorigenesis.
Current reprogramming technologies have mostly
been pursued in vitro, but recently progressed into trials
in vivo as extensively reviewed [26]. In this realm, en-
hancement of patients’ natural regenerative potential will
rely upon targeted delivery of pharmacotherapeutics or
transgenes in vivo aimed at triggering expression of
genes promoting healing, while suppressing expression
of genes promoting tumorigenesis. This will present the
next level of challenges for attaining desired efficacy in
targeting, reprogramming, and differentiation.
The first and foremost step in the preparation of stem
cells for therapeutic implantation requires that they have
to be thoroughly characterized and carefully sorted with
high throughput and under good manufacturing process
regimes to assure selection of large quantities of the
most homogeneous populations featuring high viability,
the required characteristics, and desired potential. This
effort is aided by identification of specific biomarkers
displayed on the surface of stem cells and the lineage-
specific progenitors, and developing antibodies or apta-
mers against these biomarkers, and modifications that
make them suitable for isolation on sorters. SSEA-1,
SSEA-3, and SSEA-4 were initially the targets for devel-
oping mouse monoclonal antibodies. However, they also
became the targets for developing synthetic nano-
antibodies and aptamers with superparamagnetic or fluor-
escent properties to make them suitable for high speed
magnetic or fluorescent sorters [9-11]. Research towards
identification of new biomarkers and development of new
antibodies or aptamers will surely be vigorously pursued.
As an alternative, incorporation of recombinant reporters
under pluripotency, differentiation, or inducible pro-
moters will continue. GFPs and their mutants under the
control of OCT4 or NANOG promoters are good exam-
ples of such approaches [10,11,32-34,50]. With progress in
research on stem cell genomes, transcriptomes, and pro-
teomes, new genes of interest will surely be identified and
other reporter systems designed.
Finally, one of the most pressing issues to address in re-
lation to all stem cell-based therapies is monitoring the
fate of the administered cells in vivo. This will be pursued
by continued refinement of the already developed
strategies for tracking their localization upon and after ad-
ministration, monitoring processes of differentiation to-
wards the desired lineages, detection of tumorigenesis, or
reporting deaths of therapeutically delivered cells.
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Therapeutic stem cells pose a potential risk of neoplastic
transformation. Therefore, the strategies reviewed here,
or novel strategies, that would safeguard against iatro-
genic transformation of these stem cells should be con-
sidered for incorporation into every stem cell therapy
trial.
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